Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
09 06 2023
Historique:
received: 12 05 2023
revised: 30 05 2023
accepted: 06 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Adenovirus has strong therapeutic potential as an oncolytic virus and gene therapy vector. However, injecting human species C serotype 5 adenovirus, HAdv-C5, into the bloodstream leads to numerous interactions with plasma proteins that affect viral tropism and biodistribution, and can lead to potent immune responses and viral neutralization. The HAdv/factor X (FX) interaction facilitates highly efficient liver transduction and protects virus particles from complement-mediated neutralization after intravenous delivery. Ablating the FX interaction site on the HAdv-C5 capsid leaves the virus susceptible to neutralization by natural IgM followed by activation of the complement cascade and covalent binding of complement components C4b and C3b to the viral capsid. Here we present structural models for IgM and complement components C1, C4b, and C3b in complex with HAdv-C5. Molecular dynamics simulations indicate that when C3b binds near the vertex, multiple stabilizing interactions can be formed between C3b, penton base, and fiber. These interactions may stabilize the vertex region of the capsid and prevent release of the virally encoded membrane lytic factor, protein VI, which is packaged inside of the viral capsid, thus effectively neutralizing the virus. In a situation where FX and IgM are competing for binding to the capsid, IgM may not be able to form a bent conformation in which most of its Fab arms interact with the capsid. Our structural modeling of the competitive interaction of FX and IgM with HAdv-C5 allows us to propose a mechanistic model for FX inhibition of IgM-mediated virus neutralization. According to this model, although IgM may bind to the capsid, in the presence of FX it will likely retain a planar conformation and thus be unable to promote activation of the complement cascade at the virus surface.

Identifiants

pubmed: 37376642
pii: v15061343
doi: 10.3390/v15061343
pmc: PMC10305487
pii:
doi:

Substances chimiques

Factor X 9001-29-0
Complement System Proteins 9007-36-7
Capsid Proteins 0
Immunoglobulin M 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI107960
Pays : United States
Organisme : NIH HHS
ID : AI107960
Pays : United States

Références

Nature. 1999 Oct 28;401(6756):935-8
pubmed: 10553913
EMBO J. 2011 Feb 2;30(3):606-16
pubmed: 21217642
J Virol. 2006 Dec;80(24):12049-59
pubmed: 17005667
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 2005 Jun;79(12):7478-91
pubmed: 15919903
PLoS One. 2013 Apr 19;8(4):e61571
pubmed: 23620768
Proc Natl Acad Sci U S A. 1982 Feb;79(4):1054-8
pubmed: 6175959
Protein Sci. 1997 Feb;6(2):263-74
pubmed: 9041627
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Nat Med. 2013 Apr;19(4):452-7
pubmed: 23524342
Acta Crystallogr D Struct Biol. 2016 Sep;72(Pt 9):1006-16
pubmed: 27599733
Clin Immunol. 2020 Mar;212:108351
pubmed: 32028020
Viruses. 2021 Jan 15;13(1):
pubmed: 33467558
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10183-8
pubmed: 23733956
Front Immunol. 2021 Feb 25;12:602277
pubmed: 33717083
Gene Ther. 2016 Jul;23(7):592-6
pubmed: 27014840
Cell Host Microbe. 2019 Apr 10;25(4):482-483
pubmed: 30974082
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):768-773
pubmed: 29311313
Biophys J. 2002 Mar;82(3):1190-206
pubmed: 11867437
Am J Hematol. 2023 May;98 Suppl 4:S5-S19
pubmed: 36688486
J Virol. 2017 Nov 30;91(24):
pubmed: 28978703
J Chem Phys. 2020 Jul 28;153(4):044130
pubmed: 32752662
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
Sci Transl Med. 2020 Nov 25;12(571):
pubmed: 33239388
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
Immunol Today. 1986 Jun;7(6):169-74
pubmed: 25290202
Cell. 2008 Feb 8;132(3):397-409
pubmed: 18267072
J Virol. 2005 Feb;79(4):1992-2000
pubmed: 15681401
J Immunol. 1994 Feb 1;152(3):1206-12
pubmed: 8301125
Cell Host Microbe. 2019 Apr 10;25(4):617-629.e7
pubmed: 30926239
EMBO J. 2002 Feb 1;21(3):231-9
pubmed: 11823416
Mol Ther. 2021 Feb 3;29(2):822-837
pubmed: 32949495
Pharmacol Ther. 2017 Apr;172:63-72
pubmed: 27914981
Science. 2012 Nov 9;338(6108):795-8
pubmed: 23019612
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35338084
J Immunol. 2015 Jun 1;194(11):5488-96
pubmed: 25911760
J Virol. 2009 Nov;83(22):11491-501
pubmed: 19726496
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11900-11905
pubmed: 31147461
Biochem J. 1981 Jan 1;193(1):115-27
pubmed: 7305916
J Biol Chem. 2013 May 31;288(22):15821-9
pubmed: 23592783
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5399-404
pubmed: 10805799
FEBS Lett. 2019 Dec;593(24):3449-3460
pubmed: 31660588
Mol Ther Methods Clin Dev. 2023 Mar 21;29:213-226
pubmed: 37081854
Semin Immunol. 2022 Jan;59:101627
pubmed: 35760703
Nucleic Acids Res. 2018 Jul 2;46(W1):W554-W562
pubmed: 29800260
EMBO J. 2016 May 17;35(10):1133-49
pubmed: 27013439
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5483-8
pubmed: 18391209
J Mol Biol. 2011 Mar 11;406(5):764-74
pubmed: 21146538
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):986-991
pubmed: 28104818
Radiat Oncol. 2020 Jun 12;15(1):151
pubmed: 32532291

Auteurs

Nicole Wagner (N)

Cleveland Center for Membrane and Structural Biology, Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA.

Dmitry M Shayakhmetov (DM)

Lowance Center for Human Immunology, Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
Discovery and Developmental Therapeutics Program, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

Phoebe L Stewart (PL)

Cleveland Center for Membrane and Structural Biology, Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH